Italian consensus statement on paediatric HIV infection

Infection

Volumn 38, Issue 4, 2010, Pages 301-319

  Giaquinto, C ^f   Penazzato, M ^f   Rosso, R ^r   Bernardi, S ^c   Rampon, O ^f   Nasta, P ^a   Ammassari, A ^b   Antinori, A ^b   Badolato, R ^a   Castelli Gattinara, G ^c   D'Arminio Monforte, A ^d   De Martino, M ^e   De Rossi, A ^f   Di Gregorio, P ^g   Esposito, S ^h   Fatuzzo, F ⁱ   Fiore, S ^j   Franco, A ^k   Gabiano, C ^l   Galli, L ^e   Genovese, O ^m   Giacomet, V ^j   Giannattasio, A ⁿ   Gotta, C ^o   Guarino, A ⁿ   Martino, A ^c   Mazzotta, F ^p   Principi, N ^h   Regazzi, M B ^q   Rossi, P ^c   Russo, R ^s   Saitta, M ^t   Salvini, F ^d   Trotta, S ^j   Vigano A ^j   Zuccotti, G ^j   Carosi, G ^a   more..

^a UNIVERSITY OF BRESCIA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d FATEBENEFRATELLI HOSPITAL   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g CANNIZZARO HOSPITAL   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ Universitaria Ferrarotto S Bambino   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

^k Divisione Malattie Infettive   (Italy)

^l ASO OIRM Sant'Anna   (Italy)

^m CATHOLIC UNIVERSITY   (Italy)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o UNIVERSITY OF GENOA   (Italy)

^p UOC Malattie Infettive   (Italy)

^q FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^r UNIVERSITY OF GENOA   (Italy)

^s UNIVERSITY OF CATANIA   (Italy)

^t Divisione Malattie Infettive   (Italy)

more..

Author keywords

Antiretroviral therapy; HAART; HIV; Paediatrics

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHICKENPOX VACCINE; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INFLUENZA VACCINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PNEUMOCOCCUS VACCINE; PROTEIN INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; BIRTH DEFECT; BREAST FEEDING; CHILD HEALTH; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DISEASE COURSE; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENETIC SCREENING; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; ITALY; LIFESTYLE MODIFICATION; MEDICAL SPECIALIST; METABOLIC DISORDER; MORBIDITY; MORTALITY; MOTHER CHILD RELATION; NEURAL TUBE DEFECT; NONHUMAN; OPPORTUNISTIC INFECTION; OTITIS MEDIA; PATIENT COMPLIANCE; PEDIATRICS; PERINATAL CARE; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PREGNANCY; PSYCHOSOCIAL CARE; REVIEW; RISK REDUCTION; SEXUAL BEHAVIOR; SINUSITIS; TREATMENT RESPONSE; VASCULAR DISEASE; VIRUS TRANSMISSION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DISEASE MANAGEMENT; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; ITALY; PREGNANCY;

EID: 77956059056     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-010-0020-5     Document Type: Review

References (118)

1. The Italian Register for HIV Infection in Children. Update report April 2009.
2. SL Gortmaker M Hughes J Cervia M Brady GM Johnson GR Seage 3rd LY Song WM Dankner JM Oleske Pediatric AIDS Clinical Trials Group Protocol 219 Team 2001 Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1 N Engl J Med 345 1522 1528 10.1056/NEJMoa011157 1:CAS:528:DC%2BD3MXos1Wjt7w%3D 11794218
3. P Gona RB Van Dyke PL Williams WM Dankner MC Chernoff SA Nachman GR Seage 3rd 2006 Incidence of opportunistic and other infections in HIV-infected children in the ART era JAMA 296 292 300 10.1001/jama.296.3.292 1:CAS:528:DC%2BD28XntVWqtb8%3D 16849662
4. RM Selik ML Lindegren 2003 Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999 Pediatr Infect Dis J 22 635 641 10.1097/00006454-200307000-00013 12867840
5. DM Gibb T Duong PA Tookey M Sharland G Tudor-Williams V Novelli K Butler A Riordan L Farrelly J Masters CS Peckham DT Dunn National Study of HIV in Pregnancy and Childhood Collaborative HIV Paediatric Study 2003 National Study of HIV in Pregnancy and Childhood Collaborative HIV Paediatric Study. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland BMJ 327 1019 10.1136/bmj.327.7422.1019 1:STN:280:DC%2BD3srhsVSjsw%3D%3D 14593035
6. MS McConnell RH Byers T Frederick VB Peters KL Dominguez T Sukalac AE Greenberg HW Hsu TA Rakusan IR Ortiz SK Melville MG Fowler Pediatric Spectrum of HIV Disease Consortium 2005 Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001 J Acquir Immune Defic Syndr 38 488 494 10.1097/01.qai. 0000134744.72079.cc 15764966
7. A Judd K Doerholt PA Tookey M Sharland A Riordan E Menson V Novelli EG Lyall J Masters G Tudor-Williams T Duong DM Gibb Collaborative HIV Paediatric Study (CHIPS); National Study of HIV in Pregnancy and Childhood (NSHPC) 2007 Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care Clin Infect Dis 45 918 924 10.1086/521167 17806062
8. G Carosi C Torti M Andreoni G Angarano A Antinori S Bonora M Borderi A Castagna F Castelli R Cauda F Chiodo A D'arminio-Monforte A De Luca G Di Perri F Dianzani G Filice M Galli A Lazzarin F Maggiolo R Maserati F Mazzotta M Moroni CF Perno V Vullo 2006 Key questions in antiretroviral therapy: Italian consensus workshop (2005) J Antimicrob Chemother 57 1055 1064 10.1093/jac/dkl113 1:CAS:528:DC%2BD28XmsFyktrg%3D 16606637
9. The European Mode of Delivery Collaboration. Elective caesarian-section vs. vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999;353:1035-39.
10. The International Perinatal HIV Group 1999 Mode of delivery and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies N Engl J Med 340 977 987 10.1056/NEJM199904013401301
11. C Kind C Rudin CA Siegrist CA Wyler K Biedermann U Lauper O Irion J Schüpbach D Nadal 1998 Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group AIDS 12 205 210 10.1097/00002030-199802000-00011 1:STN:280:DyaK1c7islyrug%3D%3D 9468370
12. C Thorne ML Newell 2007 HIV Semin Fetal Neonatal Med 12 174 181 10.1016/j.siny.2007.01.009 17321814
13. European HIV in Obstetrics Group 2004 Higher rates of post-partum complications in HIV infected than in uninfected women irrespective of mode of delivery AIDS 18 933 938 10.1097/00002030-200404090-00011
14. Read JS, Newell ML. Cesarean delivery for prevention of mother-to-child transmission of HIV. Cochrane Database Syst Rev 2005;4. doi: 10.1002/14651858.CD005479.
15. European Collaborative Study 2005 Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy Clin Infect Dis 40 458 465 10.1086/427287
16. ER Cooper M Charurat L Mofenson IC Hanson J Pitt C Diaz K Hayani E Handelsman V Smeriglio R Hoff W Blattner Women and Infants' Transmission Study Group 2002 Combination antiretroviral strategies for the treatment of pregnant HIV-1- infected women and prevention of perinatal HIV-1 transmission J Acquir Immune Defic Syndr 29 484 494 1:CAS:528:DC%2BD38XjvFSrt7s%3D 11981365
17. Galli L, Puliti D, Chiappini E, Gabbiano C, Ferrarsi G, Mignone F, Vigano A, Giaquinto C, Genovese O, Anzi dei G, Badolato R Buffolato W, Maccabruni A, Salvini F, Cellini M, Ruggeri M, Manzionna M, Bernardi S, Tovo P, De Martino M on behalf of Italian Register for HIV infection in children. Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1? Clin Infect Dis 2009;48:1310-17.
18. R Nduati G John D Mbori-Ngacha B Richardson J Overbaugh A Mwatha J Ndinya-Achola J Bwayo FE Onyango J Hughes J Kreiss 2000 Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial JAMA 283 1167 1174 10.1001/jama.283.9.1167 1:STN:280:DC%2BD3c7ms1Giuw%3D%3D 10703779
19. EM Connor RS Sperling R Gelber P Kiselev G Scott MJ O'Sullivan R VanDyke M Bey W Shearer RL Jacobson 1994 Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment N Engl J Med 331 1173 1180 10.1056/NEJM199411033311801 1:STN:280:DyaK2M%2FitFGmuw%3D%3D 7935654
20. The Italian Register for HIV Infection in Children 2002 Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis Arch Pediatr Adolesc Med 156 915 921
21. L Mandelbrot J Le Chenadec A Berrebi A Bongain JL Bénifla JF Delfraissy S Blanche MJ Mayaux 1998 Perinatal HIV-1 transmission-interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort JAMA 280 55 60 10.1001/jama.280.1.55 1:CAS:528:DyaK1cXks1aktbs%3D 9660364
22. A Dorenbaum CK Cunningham RD Gelber M Culnane L Mofenson P Britto C Rekacewicz ML Newell JF Delfraissy B Cunningham-Schrader M Mirochnick JL Sullivan 2002 International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. A randomized trial JAMA 288 189 198 10.1001/jama.288.2.189 1:CAS:528:DC%2BD38XltFGru7g%3D 12095383
23. KK Van Rompay JL Greenier ML Marthas MG Otsyula RP Tarara CJ Miller NC Pedersen 1995 Immediate zidovudine treatment protects simian immunodeficiency virus- infected newborn macaques against rapid onset of AIDS Antimicrob Agents Chemother 39 125 131 7695293
24. CC Tsai KE Follis A Sabo TW Beck RF Grant N Bischofberger RE Benveniste R Black 1995 Prevention of SIV infection in macaques by (R)-9-(2- phosphonylmethoxypropyl) adenine [lett] Science 270 1197 1199 10.1126/science.270.5239.1197 1:CAS:528:DyaK2MXpsVyktLY%3D 7502044
25. D Böttiger NG Johansson B Samuelsson H Zhang P Putkonen L Vrang B Oberg 1997 Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005 AIDS 11 157 162 10.1097/00002030-199702000-00004 9030361
26. NA Wade GS Birkhead BL Warren TT Charbonneau PT French L Wang JB Baum JM Tesoriero R Savicki 1998 Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus N Engl J Med 339 1409 1414 10.1056/NEJM199811123392001 1:CAS:528:DyaK1cXnsFCqt7w%3D 9811915
27. L Mandelbrot A Landreau-Mascaro C Rekacewicz A Berrebi JL Bénifla M Burgard E Lachassine B Barret ML Chaix A Bongain N Ciraru-Vigneron C Crenn-Hébert JF Delfraissy C Rouzioux MJ Mayaux S Blanche Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group 2001 Lamivudine-zidovudine combination for prevention on maternal-infant transmission of HIV-1 JAMA 285 2083 2093 10.1001/jama.285.16.2083 1:CAS:528: DC%2BD3MXjs12ju78%3D 11311097
28. Guay GE, Urban M, Chersich MF, Bolton C, van Niekerk R, Violari A, Stevens W, McIntyre JA; for the PEP Study Group. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child transmission on infants of untreated mothers. AIDS 2005;19:1289-97.
29. M Lallemant G Jourdain S Le Coeur JY Mary N Ngo-Giang-Huong S Koetsawang S Kanshana K McIntosh V Thaineua Perinatal HIV Prevention Trial (Thailand) Investigators 2000 A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators N Engl J Med 343 982 991 10.1056/NEJM200010053431401 1:CAS:528:DC%2BD3cXnsFGjs7c%3D 11018164
30. European AIDS Clinical Society. Guidelines-clinical management and treatment of HIV-infected adults in Europe 2009. http://www. europeanaidsclinicalsociety.org.
31. RS Sperling DE Shapiro RW Coombs JA Todd SA Herman GD McSherry MJ O'Sullivan RB Van Dyke E Jimenez C Rouzioux PM Flynn JL Sullivan 1996 Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to child N Engl J Med 335 1621 1629 10.1056/NEJM199611283352201 1:CAS:528:DyaK2sXot1ai 8965861
32. JS Read American Academy of Pediatrics, Committee on Pediatric AIDS 2003 Human milk, breastfeeding, and transmission of human immunodeficiency virus type 1 in the United States Pediatrics 112 1196 1205 10.1542/peds.112.5.1196 14595069
33. Centers for Disease Control and Prevention 2006 Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings MMWR 55 1 17
34. PL Havens LM Mofenson American Academy of Pediatrics, Committee on Pediatric AIDS 2008 HIV testing and prophylaxis to prevent mother-to-child transmission in the United States Pediatrics 122 1127 1134 10.1542/peds.2008- 2175
35. SA Fiscus VJ Schoenbach C Wilfert 1999 Short courses of zidovudine and perinatal transmission of HIV N Engl J Med 340 1040 1041 10.1056/ NEJM199904013401312 1:STN:280:DyaK1M7ot1ahsQ%3D%3D 10189281
36. JS Read Committee on Pediatric AIDS, American Academy of Pediatrics 2007 Diagnosis of HIV-1 infection in children younger than 18 months in the United States Pediatrics 120 1547 1562 10.1542/peds.2007-2951
37. European Collaborative Study 2004 Increased risk of adverse pregnancy outcomes in ART-treated HIV-infected women in Europe AIDS 17 2337 2339
38. Public Health Service Task Force. Safety and toxicity of individual antiretroviral agents in pregnancy. Supplement to PHSTF Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. PHSTF, 2004. http://aidsinfo.nih.gov.
39. J Le Chenadec MJ Mayaux C Guihenneuc-Jouyaux S Blanche 2003 Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants AIDS 17 2053 2061 10.1097/00002030-200309260-00006 1:CAS:528:DC%2BD3sXnsVOqt7w%3D 14502008
40. European Collaborative Study 2004 Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1 infected mothers AIDS 18 2009 2017 10.1097/00002030-200410210-00005
41. Townsend C, Schulte J, Thorne CL, Dominguez K, Cortina Borja M, Packham CS, Bohannon B, Tookey P. Exploring heterogeneity in the association between HAART and prematurity in three observational studies. 13th Observational workshop on Observational databases, Lisbon 26-28 March 2009.
42. A Noguera C Fortuny C Muñoz-Almagro E Sanchez MA Vilaseca R Artuch J Pou R Jimenez 2004 Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals Pediatrics 114 598 604 10.1542/peds.2004-0955
43. DK Ekouevi R Touré R Becquet I Viho C Sakarovitch F Rouet B Towne-Gold P Fassinou V Leroy S Blanche F Dabis Agence Nationale de Recherches Sur le SIDA 1201/1202 Ditrame Plus Study Group 2006 Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast Pediatrics 118 1071 1077 10.1542/peds.2006-0371
44. S Blanche M Tardieu P Rustin A Slama B Barret G Firtion N Ciraru-Vigneron C Lacroix C Rouzioux L Mandelbrot I Desguerre A Rötig MJ Mayaux JF Delfraissy 1999 Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues Lancet 354 1084 1089 10.1016/S0140-6736(99) 07219-0 1:CAS:528:DyaK1MXmsl2ltbw%3D 10509500
45. A Alimenti DR Burdge GS Ogilvie DM Money JC Forbes 2003 Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy Pediatr Infect Dis J 22 782 789 10.1097/01.inf. 0000086400.93257.74 14506368
46. C Giaquinto A De Romeo V Giacomet O Rampon E Ruga A Burlina A De Rossi M Sturkenboom R D'Elia 2001 Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission AIDS 15 1074 1075 10.1097/00002030-200105250-00023 1:STN:280:DC%2BD3MzjtVymuw%3D%3D 11399997
47. K Dominguez J Bertolli M Fowler V Peters I Ortiz S Melville T Rakusan T Frederick H Hsu P D'Almada Y Maldonado C Wilfert PSD Consortium. Perinatal Safety Review Working Group 2000 Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA Ann N Y Acad Sci 918 236 246 10.1111/j.1749-6632.2000.tb05493.x 1:STN:280: DC%2BD3M%2FnvVyhtA%3D%3D 11131710
48. The European Collaborative Study 1997 Hospitalization of children born to human immunodeficiency virus infected women in Europe Pediatr Infect Dis J 16 1151 1156 10.1097/00006454-199712000-00010
49. D Dunn P Woodburn T Duong J Peto A Phillips D Gibb K Porter HIV paediatric Prognostic Markers Collaborative Study (HPPMCS), Concerned action on Sero-Conversion TO aids AND death in Europe (CASCADE) Collaboration 2008 Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults J Infect Dis 197 398 404 10.1086/524686 18248303
50. AS Walker K Doerholt M Sharland DM Gibb Collaborative HIV Paediatric Study (CHIPS) Steering Committee 2004 Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study AIDS 18 1915 1924 10.1097/00002030-200409240-00007 15353977
51. D Gibb C Giaquinto 2000 Children with HIV infection: special cases Lancet 356 s34 10.1016/S0140-6736(00)92020-8 11191491
52. L Ometto D De Forni F Patiri V Trouplin F Mammano V Giacomet C Giaquinto D Douek R Koup A De Rossi 2002 Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness AIDS 16 839 849 10.1097/00002030-200204120-00003 11919485
53. The European Collaborative Study 1992 Age-related standards for T lymphocytes subsets based on uninfected children born to HIV-infected women Pediatr Infect Dis J 11 1018 1026 10.1097/00006454-199211120-00006
54. A Kovacs G Montepiedra V Carey S Pahwa A Weinberg L Frenkel E Capparelli L Mofenson E Smith K McIntosh SK Burchett Pediatric AIDS Clinical Trials Group 366 Study Team 2005 Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response J Infect Dis 192 296 302 10.1086/430922 15962224
55. A De Rossi AS Walker N Klein D De Forni D King DM Gibb 2002 Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial J Infect Dis 186 312 320 10.1086/341657 12134227
56. P Bagnarelli M Vecchi N Burighel D Bellanova S Menzo M Clementi A De Rossi 2004 Genotypic and phenotypic correlates of the HIV type 1 env gene evolution in infected children with discordant response to antiretroviral therapy AIDS Res Hum Retrovir 20 1306 1313 10.1089/aid.2004.20.1306 1:CAS:528:DC%2BD2MXpsFWntQ%3D%3D 15650423
57. K Patel PENTA group 219 study team, et al. 2008 Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting Clin Infect Dis 46 1751 1760 10.1086/587900 1:CAS:528:DC%2BD1cXnsVOhtbw%3D 18426371
58. E Chiappini L Galli PA Tovo C Gabiano C Lisi GC Gattinara S Esposito A Viganò C Giaquinto C Rosso A Guarino M De Martino 2007 Changing patterns of clinical events inperinatally HIV-1 infected children during the era of HAART AIDS 21 1607 1615 10.1097/QAD.0b013e32823ecf5b 17630556
59. World Health Organisation: Antiretroviral therapy for HIV infection in infants and children: Towards universal access Recommendations for a public health approach http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf.
60. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 23, 2009; pp 1-139. http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf.
61. M Sharland S Blanche G Castelli J Ramos DM Gibb on behalf of the PENTA Steering Committee 2004 PENTA guidelines for the use of antiretroviral therapy, 2004 HIV Med 5 61 86 10.1111/j.1468-1293.2004.00227.x 15239717
62. M Zanchetta A Anselmi D Vendrame O Rampon C Giaquinto A Mazza D Accapezzato V Barnaba A De Rossi 2008 HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response Antivir Therapy 13 47 55 1:CAS:528:DC%2BD1cXksVegsb8%3D
63. P Palma ML Romiti C Cancrini S Pensieroso C Montesano S Bernardi M Amicosante S Di Cesare G Castelli-Gattinara B Wahren P Rossi 2008 Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants Vaccine 26 5196 5201 10.1016/j.vaccine.2008.03.062 1:CAS:528:DC%2BD1cXhtVygurjF 18471944
64. GL Kearns SM Abdel-Rahman SW Alander DL Blowey JS Leeder RE Kauffman 2003 Developmental pharmacology-drug disposition, action, and therapy in infants and children N Engl J Med 349 1157 1167 10.1056/NEJMra035092 1:CAS:528: DC%2BD3sXnsV2jtbo%3D 13679531
65. PL Fraaij N Rakhmanina D Burger R de Groot 2004 Therapeutic drug monitoring in children with HIV/AIDS Ther Drug Monit 26 122 126 10.1097/00007691-200404000-00006 15228151
66. HIV Paediatric Prognostic Markers Collaborative Study Group 2006 Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children AIDS 20 1289 1294 10.1097/01.aids.0000232237.20792.68
67. ML Newell D Patel T Goetghebuer C Thorne European Collaborative Study 2006 CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis 193 954 962 10.1086/500842 1:CAS:528:DC%2BD28XjsVCgs70%3D 16518757
68. A Faye J Le Chenadec C Dollfus I Thuret D Douard G Firtion E Lachassinne M Levine J Nicolas F Monpoux J Tricoire C Rouzioux M Tardieu MJ Mayaux S Blanche French Perinatal Study Group 2004 Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1 Clin Infect Dis 39 1692 1698 10.1086/425739 15578372
69. E Chiappini L Galli PA Tovo C Gabiano GC Gattinara A Guarino R Badolato C Giaquinto C Lisi M de Martino 2006 Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection AIDS 20 207 215 10.1097/01.aids.0000200529.64113.3e 1:CAS:528:DC%2BD28XhvFCks7g%3D 16511413
70. D Van der Linden M Hainaut T Goetghebuer E Haelterman V Schmitz P Maes A Peltier J Levy 2007 Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants Pediatr Infect Dis J 26 359 361 10.1097/01.inf. 0000258626.34984.eb 17414406
71. Aboulker JP, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debre M, Faye A, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004;18:237-245.
72. T Goetghebuer E Haelterman J Le Chenadec C Dolfus D Gibb A Judd H Green L Galli JT Ramos C Giaquinto J Warszawki J Levy for the European Infant Collaboration Group 2009 Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants AIDS 23 597 604 10.1097/QAD.0b013e328326ca37 19194272
73. A Violari MF Cotton DM Gibb AG Babiker J Steyn SA Madhi P Jean-Philippe JA McIntyre CHER Study Team 2008 Early antiretroviral therapy and mortality among HIV-infected infants N Engl J Med 359 2233 2244 10.1056/NEJMoa0800971 1:CAS:528:DC%2BD1cXhtl2gurbM 19020325
74. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355: 2283-96.
75. Emery S, SMART Study Group and INSIGHT. Major clinical outcomes in patients not treated with antiretroviral therapy at baseline in SMART: a rationale for a trial to examine early treatment of HIV disease [Abstract WEPEB018]. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia, 2007.
76. AN Phillips B Gazzard R Gilson P Easterbrook M Johnson J Walsh C Leen M Fisher C Orkin J Anderson D Pillay V Delpech C Sabin A Schwenk D Dunn M Gompels T Hill K Porter A Babiker UK Collaborative HIV Cohort Study 2007 Rate of AIDS diseases or death in HIV infected antiretroviral therapy-naive individuals with high CD4 cell count AIDS 21 1717 2721 10.1097/QAD.0b013e3282170a9d 17690569
77. H Green DM Gibb AS Walker D Pillay K Butler F Candeias G Castelli-Gattinara A Compagnucci M Della Negra A de Rossi C Feiterna-Sperling C Giaquinto L Harper J Levy Y Saidi U Wintergerst 2007 Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children AIDS 21 947 955 10.1097/QAD.0b013e3280e087e7 1:STN:280: DC%2BD2s3kvVejsg%3D%3D 17457088
78. E DeJesus G Herrera E Teofilo J Gerstoft CB Buendia JD Brand CH Brothers J Hernandez SA Castillo T Bonny ER Lanier TR Scott CNA30024 Study Team 2004 Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults Clin Infect Dis 39 1038 1046 10.1086/424009 1:CAS:528:DC%2BD2cXptFKjs7g%3D 15472858
79. AM Wensing DA van de Vijver G Angarano B Asjö C Balotta E Boeri R Camacho ML Chaix D Costagliola A De Luca I Derdelinckx Z Grossman O Hamouda A Hatzakis R Hemmer A Hoepelman A Horban K Korn C Kücherer T Leitner C Loveday E MacRae I Maljkovic C de Mendoza L Meyer C Nielsen EL Op de Coul V Ormaasen D Paraskevis L Perrin E Puchhammer-Stöckl L Ruiz M Salminen JC Schmit F Schneider R Schuurman V Soriano G Stanczak M Stanojevic AM Vandamme K Van Laethem M Violin K Wilbe S Yerly M Zazzi CA Boucher SPREAD Programme 2005 Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management J Infect Dis 192 958 966 10.1086/432916 16107947
80. P Cane I Chrystie D Dunn B Evans AM Geretti H Green A Phillips D Pillay K Porter A Pozniak C Sabin E Smit J Weber M Zuckerman UK Group on Transmitted HIV Drug Resistance 2005 Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study BMJ 332 179 180
81. RM Novak L Chen RD MacArthur JD Baxter K Huppler Hullsiek G Peng Y Xiang C Henely B Schmetter J Uy M van den Berg-Wolf M Kozal Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team 2005 Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy Clin Infect Dis 40 468 474 10.1086/427212 1:CAS:528:DC%2BD2MXhs12gurw%3D 15668873
82. Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N, Wilson CM; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Prevalence of primary HIV drug resistance among recently infected adolescents: a multicenter Adolescent Trials Network study: ATN 029. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Abstract # 21.
83. DL Paterson S Swindells J Mohr M Brester EN Vergis C Squier MM Wagener N Singh 2000 Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Intern Med 133 21 30 1:STN:280:DC%2BD3czit1altA%3D%3D 10877736
84. RB Van Dyke S Lee GM Johnson A Wiznia K Mohan K Stanley EV Morse PA Krogstad S Nachman Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team 2002 Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection Pediatrics 109 61 10.1542/peds.109.4.e61
85. DC Watson JJ Farley 1999 Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1 Pediatr Infect Dis J 18 682 689 10.1097/00006454-199908000-00006 1:STN:280:DyaK1MzovFCgsA%3D%3D 10462336
86. PM Flynn BJ Rudy SD Douglas J Lathey SA Spector J Martinez M Silio M Belzer L Friedman L D'Angelo J McNamara J Hodge MD Hughes JC Lindsey Pediatric AIDS Clinical Trial Group 381 Study Team 2004 Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy J Infect Dis 190 271 279 10.1086/421521 1:CAS:528:DC%2BD2cXmsFaqtL8%3D 15216461
87. AA Howard JH Arnsten Y Lo D Vlahov JD Rich P Schuman VE Stone DK Smith EE Schoenbaum HER Study Group 2002 A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women AIDS 16 2175 2182 10.1097/00002030-200211080-00010 1:CAS:528:DC%2BD38XosFegtbg%3D 12409739
88. DA Murphy M Sarr SJ Durako AB Moscicki CM Wilson LR Muenz Adolescent Medicine HIV/AIDS Research Network 2003 Adolescent Medicine HIV/AIDS Research Network. Barriers to ART adherence among human immunodeficiency virus-infected adolescents Arch Pediatr Adolesc Med 157 249 255 10.1001/archpedi.157.6.560 12622674
89. Gibb DM on behalf of the PENTA 11 team. Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA 11 trial). J Int AIDS Soc. 2008;11, abs 021.
90. M Ryan S Griffin B Chitah AS Walker V Mulenga D Kalolo N Hawkins C Merry MG Barry C Chintu MJ Sculpher DM Gibb 2008 The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia AIDS 22 749 757 10.1097/QAD.0b013e3282f43519 18356605
91. WHO (2006) Guidelines on co-trimoxazole prophylaxis for HIV related infections among children, adolescents, and adults in resource-limited settings. http://www.who.int/hiv/pub/guidelines/ctx/en/index.html.
92. S Nachman P Gona W Dankner A Weinberg R Yogev A Gershon M Rathore JS Read S Huang C Elgie K Hudgens W Hughes 2005 The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis Pediatrics 115 488 494 10.1542/peds.2004-1847
93. S Esposito J Bojanin A Porta L Cesati L Gualtieri N Principi 2005 Discontinuation of secondary prophylaxis for Pneumocystis Pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy Pediatr Infect Dis J 24 1117 1120 10.1097/01.inf. 0000190038.53813.d2 16371882
94. H Furrer M Egger M Opravil E Bernasconi B Hirschel M Battegay A Telenti PL Vernazza M Rickenbach M Flepp R Malinverni 1999 Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study N Engl J Med 340 1301 1306 10.1056/NEJM199904293401701 1:STN:280:DyaK1M3hvFOlsQ%3D%3D 10219064
95. B Ledergerber A Mocroft P Reiss H Furrer O Kirk M Bickel C Uberti-Foppa C Pradier A D'Arminio Monforte MM Schneider JD Lundgren Eight European Study Groups 2001 Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups N Engl J Med 344 168 174 10.1056/NEJM200101183440302 1:CAS:528:DC%2BD3MXosleksg%3D%3D 11188837
96. WM Dankner JC Lindsey MJ Levin Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327 2001 Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy Pediatr Infect Dis J 20 40 48 10.1097/00006454-200101000-00008 1:STN:280:DC%2BD38%2FgsFarsA%3D%3D 11176565
97. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group 1991 Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection N Engl J Med 325 73 80
98. SA Spector RD Gelber N McGrath D Wara A Barzilai E Abrams YJ Bryson WM Dankner RA Livingston EM Connor 1994 A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group N Engl J Med 331 1181 1187 10.1056/NEJM199411033311802 1:STN:280:DyaK2M%2FitFGlsg%3D%3D 7935655
99. WJ Moss CJ Clements NA Halsey 2003 Immunization of children, at risk of infection with human immunodeficiency virus Bull World Health Organ 81 61 70 12640478
100. E Traggiai R Puzone A Lanzavecchia 2003 Antigen dependent and independent mechanisms that sustain serum antibody levels Vaccine 21 S35 S37 10.1016/S0264-410X(03)00198-1 12763680
101. E Tanzi S Esposito J Bojanin A Amendola D Trabattoni E Pariani R Pinzani A Zanetti N Principi 2006 Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy J Med Virol 78 440 445 10.1002/jmv.20559 16482542
102. WJ Moss CJ Clements NA Halsey 2003 Immunization of children, at risk of infection with human immunodeficiency virus Bull World Health Organ 81 61 70 12640478
103. European Paediatric Lipodystrophy Group 2004 Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe AIDS 18 1443 1451 10.1097/01.aids.0000131334.38172.01
104. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
105. RB Van Dyke L Wang PL Williams Pediatric AIDS Clinical Trials Group 219C Team 2008 Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children J Infect Dis 198 1599 1608 10.1086/593022 19000014
106. A Vigano V Giacomet G Pattarino S Fasan G Zuccotti P Brambilla 2007 Metabolic complications of HIV infection and its therapy in children Futur HIV Therapy 1 181 190 10.2217/17469600.1.2.181 1:CAS:528:DC%2BD2sXptV2jsb8%3D
107. P Rietschel C Hadigan C Corcoran T Stanley G Neubauer J Gertner S Grinspoon 2005 Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy J Clin Endocrinol Metab 90 4075 4080 10.1210/jc.2004-2431
108. A Viganò P Brambilla L Cafarelli V Giacomet S Borgonovo I Zamproni G Zuccotti S Mora 2007 Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz Antivir Ther 12 297 302 17591019
109. SM Arpadi PA Cuff M Horlick J Wang DP Kotler 2001 Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine J Acquir Immune Defic Syndr 27 30 34 1:STN:280: DC%2BD3Mzjs1Cmuw%3D%3D 11404517
110. A Viganò GM Aldrovandi V Giacomet M Merlo L Martelli S Beretta P Luraschi G Rombolà S Mora 2005 Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children Antivir Ther 10 917 924 16430197
111. M Charakida D Tousoulis I Skoumas C Pitsavos C Vasiliadou E Stefanadi C Antoniades G Latsios G Siasos C Stefanadis 2009 Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia Atherosclerosis 204 532 537 10.1016/j.atherosclerosis.2008. 09.025 1:CAS:528:DC%2BD1MXmtl2ltL0%3D 19004443
112. Viganò A, Cerini C, Meroni L, Giacomet V, Fabiano V et al. Long term HIV infection is associated with increased carotid intima media thickness in HIV infected adolescents. 16th Conference on Retroviruses and Opportunistic Infections, Montreal 2009, Abstract 915.
113. P Lester M Chesney M Cooke R Weiss P Whalley B Perez D Glidden A Petru A Dorenbaum D Wara 2002 When the time comes to talk about HIV: factors associated with diagnostic disclosure and emotional distress in HIV-infected children J Acquir Immune Defic Syndr. 3 309 317
114. SL Instone 2000 Perceptions of children with HIV infection when not told for so long: implications for diagnosis disclosure J Pediatr Health Care 14 235 243 1:STN:280:DC%2BD383ltlGhtw%3D%3D 11005886
115. PJ Bachanas KA Kullgren KS Schwartz B Lanier JS McDaniel J Smith S Nesheim 2001 Predictors of psychological adjustment in school-age children infected with HIV J Pediatr Psychol 26 343 352 10.1093/jpepsy/26.6.343 1:STN:280:DC%2BD3Mvktl2guw%3D%3D 11490035
116. CA Mellins E Brackis-Cott C Dolezal EJ Abrams 2006 Psychiatric disorders in youth with perinatally acquired human immunodeficiency virus infection Pediatr Infect Dis J 25 432 437 10.1097/01.inf.0000217372.10385.2a 16645508
117. ME Belzer DN Fuchs GS Luftman DJ Tucker 1999 Antiretroviral adherence issues among HIV-positive adolescents and young adults J Adolesc Health 25 316 319 10.1016/S1054-139X(99)00052-X 1:STN:280:DC%2BD3c%2FhslyhsA%3D%3D 10551660
118. V Giacomet F Albano F Starace A de Franciscis C Giaquinto GC Gattinara E Bruzzese C Gabiano L Galli A Viganò D Caselli A Guarino 2003 Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study Acta Paediatr 92 1398 1402 10.1080/08035250310006737 1:STN:280:DC%2BD2c%2Fot1aguw%3D%3D 14971789